Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 0.09, near the low end of its 5-year range (-0.48–20.31).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
-0.05
DEBT TO EQUITY RATIO AVG 5Y
0.09
DEBT TO EQUITY RATIO AVG 10Y
0.11
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Mustang Bio, Inc.
Market Cap
$3.49M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
-0.05
5Y Avg
0.09
Market Cap
$3.53M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$3.50M
Debt to Equity Ratio
7.21
TTM Avg
1.21
3Y Avg
0.62
5Y Avg
0.62
Market Cap
$3.63M
Debt to Equity Ratio
0.22
TTM Avg
0.35
3Y Avg
0.76
5Y Avg
0.72
Market Cap
$3.30M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$3.65M
Debt to Equity Ratio
0.11
TTM Avg
0.30
3Y Avg
4.92
5Y Avg
3.36
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mustang Bio, Inc. (MBIO) | $3.49M | 0.00 | 0.00 | -0.05 | 0.09 |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Moolec Science S.A. (MLEC)vs › | $3.50M | 7.21 | 1.21 | 0.62 | 0.62 |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | 0.22 | 0.35 | 0.76 | 0.72 |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A | 0.69 | 0.37 | 0.26 |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | 0.00 | 0.00 | 0.04 | 0.04 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | 0.11 | 0.30 | 4.92 | 3.36 |
| MBody AI Ltd. (MBAI)vs › | $3.25M | 0.00 | 0.00 | 0.01 | 0.01 |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | 0.02 | 0.06 | 0.17 | 0.12 |
Debt/Equity
0.00
Current Ratio
1.97
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | -0.23 |
| 2024-09-30 | -0.11 |
| 2024-06-30 | -0.13 |
| 2024-03-31 | -0.48 |
| 2023-12-31 | 20.31 |
| 2023-09-30 | 0.64 |
| 2023-06-30 | 0.19 |
| 2023-03-31 | 1.06 |
| 2022-12-31 | 0.68 |
| 2022-09-30 | 0.49 |
| 2022-06-30 | 0.35 |
| 2022-03-31 | 0.30 |
| 2021-12-31 | 0.02 |
| 2021-09-30 | 0.02 |
| 2021-06-30 | 0.02 |
| 2021-03-31 | 0.02 |
| 2020-12-31 | 0.02 |
| 2020-09-30 | 0.03 |
| 2020-06-30 | 0.23 |
| 2020-03-31 | 0.35 |
| 2019-12-31 | 0.30 |
| 2019-09-30 | 0.25 |
| 2019-06-30 | 0.21 |
| 2019-03-31 | 0.52 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.01 |
| 2016-09-30 | 1.48 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
